SCO-240 is under clinical development by Scohia Pharma and currently in Phase I for Growth Hormone Deficiency.

"In people with progressive cognitive decline, the diagnosis of Alzheimer's disease requires a demonstration of amyloid and ...

Hormones do a lot throughout a person’s lifespan. Most people associate hormones with development and sex. Learn about their ...

FDA approves Crenessity a groundbreaking drug for classic congenital adrenal hyperplasia CAH reducing steroid use and offering new hope for patients with this rare disorder ...

0139), showcases Professor Neumann's pioneering research on neuropeptides, particularly oxytocin, which has evolved far beyond its popular characterization as simply the "love hormone." ...

The goal of hormone therapy is to manage the symptoms of menopause, not necessarily to restore or return to your previous hormone levels. Menopause is a biological process that many people will ...

Human growth hormone (HGH) is a hormone that’s essential to our development. Most people produce enough HGH throughout their lifetime. But for those with a deficiency in growth hormone (or a few ...

“Growth hormone therapy typically requires daily ... Our approved products in Japan include therapies for the treatment of growth disorder, MPS II (Hunter syndrome), Fabry disease, acute graft ...

Background and aims: Acquired resistance to thyroid hormone appears to exist in the general population ... We also excluded participants previously diagnosed with thyroid disorders, those who were ...

Bipolar I disorder is a mental health condition that causes extreme ups and downs in mood and energy. You might hear it called “manic-depressive disorder” or “manic depression,” which are ...

(NASDAQ:IRON), a biotechnology company with a market capitalization of $1.93 billion focused on developing treatments for rare blood disorders, has been garnering attention from analysts ... This ...